Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150035/S038

Aveir VR (LSCD111); DR Delivery Catheter (LSCD201)

ABBOTT MEDICAL · Decision date May 29, 2026

FDA DECISIONP150035/S038

What did the FDA approve?

FDA records P150035/S038 as a supplement to PMA P150035, with the supplement type “Real-Time Process”. The recorded decision is approval, dated May 29, 2026.

FDA approval order statement

Approval for a revised design for the AVEIR delivery catheters packaging trays and retainers as well as a shelf-life extension for both delivery catheters.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
May 29, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P150035/S038
Regulatory pathway
PMA supplement
Product code
PNJ
Decision code
APPR
Decision date
May 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Leadless pacemaker.

Product code
PNJ
FDA device class
3

For the original device and its historical approval scope, see PMA P150035. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150035 · Original PMA

    Aveir VR Leadless System

  2. P150035/S029 · Related supplement

    AVEIR AR 2 LSP203A Leadless Pacemaker (LP) (atrial)

  3. P150035/S031 · Related supplement

    AVEIR Leadless Pacemaker

  4. P150035/S030 · Related supplement

    Aveir VR Delivery Catheter LSCD111; Aveir DR Delivery Catheter LSCD201

  5. P150035/S028 · Related supplement

    AVEIR Patient Transmitter (model, LSRM01), AVEIR Patient Transmitter Software (model, LSRM1000 v 1.0), AVEIR Patient T

  6. P150035/S032 · Related supplement

    AVEIR Leadless Pacemaker Real-time Clock (RTC) electrical test

  7. P150035/S033 · Related supplement

    Aveir VR Leadless Pacemaker; Aveir Leadless Pacemaker (Right Atrium); Aveir Leadless Pacemaker (Right Ventricle)

  8. P150035/S026 · Related supplement

    Aveir VR Leadless Pacemaker, Aveir Leadless Pacemaker (Right Ventricular)

  9. P150035/S034 · Related supplement

    Aveir DR Delivery Catheter (LSCD201)

  10. P150035/S038 received

    Application receipt date recorded by FDA.

  11. P150035/S036 · Related supplement

    AVEIR Leadless Pacemaker, ventricular (LSP112V, LSP202V); Aveir Delivery Catheter (LSCD111, LSCD201)

  12. P150035/S038 · FDA decision

    Real-Time Process

  13. P150035/S039 · Related supplement

    The AVEIR Leadless Pacemaker (LP)

  14. P150035/S040 · Related supplement

    AVEIR Patient Transmitter LSRM01

  15. P150035/S041 · Related supplement

    Aveir VR Leadless System

  16. P150035/S042 · Related supplement

    AVEIR VR Real-World Evidence Study

Timeline entries are records held by MedtechLedger for P150035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150035

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalMar 31, 2022FDA
ABBOTT MEDICALPMA supplementAug 15, 2025FDA
ABBOTT MEDICALPMA supplementSep 5, 2025FDA
ABBOTT MEDICALPMA supplementSep 17, 2025FDA
ABBOTT MEDICALPMA supplementSep 24, 2025FDA
ABBOTT MEDICALPMA supplementSep 30, 2025FDA
ABBOTT MEDICALPMA supplementOct 28, 2025FDA
ABBOTT MEDICALPMA supplementFeb 19, 2026FDA
ABBOTT MEDICALPMA supplementFeb 23, 2026FDA
ABBOTT MEDICALPMA supplementApr 3, 2026FDA
ABBOTT MEDICALPMA supplementApr 24, 2026FDA
ABBOTT MEDICALPMA supplementJun 11, 2026FDA
ABBOTT MEDICALPMA supplementJun 17, 2026FDA
ABBOTT MEDICALPMA supplementJul 21, 2026FDA
ABBOTT MEDICALPMA supplementAug 27, 2026FDA
ABBOTT MEDICALPMA supplementOct 21, 2026FDA

Explore the linked device profile

Other records with product code PNJ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
15900 Valley View Ct., Sylmar, CA, 91342

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records